FDA Clears IND to Study Gene Therapy CAP-002 in STXBP1 Developmental Epileptic Encephalopathy

FDA approves study to test Capsida’s CAP-002 gene therapy for STXBP1-DEE, offering hope for improved seizure control and developmental outcomes in affected patients.:

Source: Neurology Read More